Manesh Girn
Postdoctoral Neuroscientist at UCSF; Scientific Director at The Center for Minds
Data updated
Research Footprint
Manesh Girn appears in 10 tracked papers (2020–2026), most studied alongside Psilocybin, LSD and DMT, across Neuroimaging & Brain Measures, Healthy Volunteers and Depressive Disorders.
Most-cited paper: Human brain effects of DMT assessed via EEG-fMRI (213 citations).
Frequent co-authors: Robin Carhart-Harris, Leor Roseman and David Nutt.
Background & Research
Manesh Girn is a postdoctoral neuroscientist at the University of California, San Francisco (UCSF), where he studies the brain mechanisms underlying the psychedelic experience and psychedelic-assisted therapy. He earned his PhD in Neuroscience at McGill University, focusing on the default-mode network and its relationship to complex cognition and the psychedelic experience. He is also the Scientific Director at The Center for Minds and runs The Psychedelic Scientist, a science education platform.
Key Impact
He is a neuroscientist whose work on psychedelic brain networks, including psilocybin, LSD, and DMT, has helped shape contemporary understanding of how psychedelics alter brain organization and cognition.
Collaboration Network
35 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Manesh Girn is associated with.
University of California, San Francisco
academicUniversity of California, San Francisco (UCSF) hosts major psychedelic research activity through the Translational Psychedelic Research Program (TrPR), Neuroscape Psychedelics Division, and psychiatry-led clinical research on psychedelic-assisted therapies.
View stakeholder →McGill University
A leading Canadian research university in Montreal, Quebec, McGill pioneered the “Montreal Model”—an integrative biomedical-psychedelic approach to ketamine-assisted psychotherapy for severe treatment-resistant depression developed over 6 years and 500+ ketamine treatments. The team’s MUSIK randomized trial demonstrated that emotional and mystical ketamine experiences within a structured therapeutic environment drive more sustained antidepressant improvements, including in ketamine vs. ECT comparison trials.
View stakeholder →